Exelixis, Inc. – NASDAQ:EXEL
Founder-led company
Exelixis stock price today
$37.54
+3.72
+11.03%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
Exelixis stock price monthly change
+50.94%
month
Exelixis stock price quarterly change
+50.94%
quarter
Exelixis stock price yearly change
+40.58%
year
Exelixis key metrics
Market Cap | 9.47B |
Enterprise value | 6.14B |
P/E | 34.62 |
EV/Sales | 3.81 |
EV/EBITDA | 23.05 |
Price/Sales | 4.00 |
Price/Book | 2.59 |
PEG ratio | -1.55 |
EPS | 0.65 |
Revenue | 1.84B |
EBITDA | 250.09M |
Income | 205.05M |
Revenue Q/Q | 4.02% |
Revenue Y/Y | 10.98% |
Profit margin | 11.31% |
Oper. margin | 12.51% |
Gross margin | 96.41% |
EBIT margin | 12.51% |
EBITDA margin | 13.54% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeExelixis stock price history
Exelixis stock forecast
Exelixis financial statements
Average Price Target
$30.85
Potential downside: -17.81%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 469.84M | 81.17M | 17.28% |
|---|---|---|---|
| Sep 2023 | 471.92M | 1.04M | 0.22% |
| Dec 2023 | 479.65M | 85.51M | 17.83% |
| Mar 2024 | 425.22M | 37.31M | 8.78% |
| Jun 2023 | 3142468000 | 614.53M | 19.56% |
|---|---|---|---|
| Sep 2023 | 2976910000 | 629.29M | 21.14% |
| Dec 2023 | 2942357000 | 678.44M | 23.06% |
| Mar 2024 | 2803752000 | 675.74M | 24.1% |
| Jun 2023 | 120.97M | -73.78M | -124.79M |
|---|---|---|---|
| Sep 2023 | 117.36M | 34.68M | -219.67M |
| Dec 2023 | 10.57M | 61.73M | -206.17M |
| Mar 2024 | 68.82M | 111.79M | -184.04M |
Exelixis alternative data
| Aug 2023 | 1,223 |
|---|---|
| Sep 2023 | 1,223 |
| Oct 2023 | 1,223 |
| Nov 2023 | 1,223 |
| Dec 2023 | 1,223 |
| Jan 2024 | 1,223 |
| Feb 2024 | 1,223 |
| Mar 2024 | 1,310 |
| Apr 2024 | 1,310 |
| May 2024 | 1,310 |
| Jun 2024 | 1,310 |
| Jul 2024 | 1,310 |
Exelixis other data
84.73%
+2.31%
of EXEL is owned by hedge funds
356
+11
273.93M
+8.23M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 114149 |
| Feb 2024 | 190000 | 47020 |
| Mar 2024 | 0 | 19205 |
| May 2024 | 425000 | 61326 |
| Jun 2024 | 0 | 8287 |
| Aug 2024 | 0 | 396858 |
| Sep 2024 | 0 | 25000 |
| Oct 2024 | 0 | 26162 |
| Nov 2024 | 0 | 288574 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HESSEKIEL JEFFREY officer: EVP & Ge.. | Common Stock | 60,000 | $36.67 | $2,200,200 | ||
Option | HESSEKIEL JEFFREY officer: EVP & Ge.. | Common Stock | 129,314 | $18.8 | $2,431,103 | ||
Option | HESSEKIEL JEFFREY officer: EVP & Ge.. | Option (right to buy) | 129,314 | $18.8 | $2,431,103 | ||
Sale | HALEY PATRICK J. officer: EVP, Commercial | Common Stock | 10,000 | $35.27 | $352,700 | ||
Sale | HALEY PATRICK J. officer: EVP, Commercial | Common Stock | 22,207 | $34.31 | $761,922 | ||
Sale | HALEY PATRICK J. officer: EVP, Commercial | Common Stock | 19,381 | $34.41 | $666,900 | ||
Option | AFTAB DANA officer: CSO/EVP Disc & Trans R.. | Common Stock | 96,986 | $18.8 | $1,823,337 | ||
Sale | AFTAB DANA officer: CSO/EVP Disc & Trans R.. | Common Stock | 96,986 | $35 | $3,394,510 | ||
Option | AFTAB DANA officer: CSO/EVP Disc & Trans R.. | Option (right to buy) | 96,986 | $18.8 | $1,823,337 | ||
Sale | HESSEKIEL JEFFREY officer: EVP & Ge.. | Common Stock | 50,000 | $34.13 | $1,706,500 |
| Quarter | Transcript |
|---|---|
| Q1 2024 30 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Michael M. Morrissey (1961) Chief Executive Officer, Pres & Director | $2,350,000 |
| Mr. Christopher J. Senner (1968) Executive Vice President & Chief Financial Officer | $1,060,000 |
| Mr. Jeffrey J. Hessekiel (1969) Executive Vice President, Gen. Counsel & Sec. | $916,910 |
Mr. Patrick J. Haley M.B.A., MBA (1976) Executive Vice President of Commercial | $801,650 |
| Dr. Stelios Papadopoulos Ph.D. (1948) Co-Founder & Independent Chairman | $98,000 |
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
The Best Defensive Stocks To Hedge Against Market Uncertainty
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
Exelixis: With Patent Litigation Decision Due Soon, There Are Options
Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
5 Biotech Acquisition Targets To Accumulate In 2024
Ajinomoto: Food, Biotech, And Semis All-In-One
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
-
What's the price of Exelixis stock today?
One share of Exelixis stock can currently be purchased for approximately $37.54.
-
When is Exelixis's next earnings date?
Unfortunately, Exelixis's (EXEL) next earnings date is currently unknown.
-
Does Exelixis pay dividends?
No, Exelixis does not pay dividends.
-
How much money does Exelixis make?
Exelixis has a market capitalization of 9.47B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 13.6% to 1.83B US dollars.
-
What is Exelixis's stock symbol?
Exelixis, Inc. is traded on the NASDAQ under the ticker symbol "EXEL".
-
What is Exelixis's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Exelixis?
Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Exelixis's key executives?
Exelixis's management team includes the following people:
- Dr. Michael M. Morrissey Chief Executive Officer, Pres & Director(age: 64, pay: $2,350,000)
- Mr. Christopher J. Senner Executive Vice President & Chief Financial Officer(age: 57, pay: $1,060,000)
- Mr. Jeffrey J. Hessekiel Executive Vice President, Gen. Counsel & Sec.(age: 56, pay: $916,910)
- Mr. Patrick J. Haley M.B.A., MBA Executive Vice President of Commercial(age: 49, pay: $801,650)
- Dr. Stelios Papadopoulos Ph.D. Co-Founder & Independent Chairman(age: 77, pay: $98,000)
-
Is Exelixis founder-led company?
Yes, Exelixis is a company led by its founder Dr. Stelios Papadopoulos Ph.D..
-
How many employees does Exelixis have?
As Jul 2024, Exelixis employs 1,310 workers.
-
When Exelixis went public?
Exelixis, Inc. is publicly traded company for more then 25 years since IPO on 17 Apr 2000.
-
What is Exelixis's official website?
The official website for Exelixis is exelixis.com.
-
Where are Exelixis's headquarters?
Exelixis is headquartered at 1851 Harbor Bay Parkway, Alameda, CA.
-
How can i contact Exelixis?
Exelixis's mailing address is 1851 Harbor Bay Parkway, Alameda, CA and company can be reached via phone at +65 08377000.
-
What is Exelixis stock forecast & price target?
Based on 14 Wall Street analysts` predicted price targets for Exelixis in the last 12 months, the avarage price target is $30.85. The average price target represents a -17.81% change from the last price of $37.54.
Exelixis company profile:
Exelixis, Inc.
exelixis.comExchange:
NASDAQ
Full time employees:
1,310
Industry:
Biotechnology
Sector:
Healthcare
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
1851 Harbor Bay Parkway
Alameda, CA 94502
Alameda, CA 94502
CIK: 0000939767
ISIN: US30161Q1040
CUSIP: 30161Q104
